Drug testing services firm Inotiv's Q4 revenue beats estimates

Inotiv

03/12/2025 21:21

Overview

Inotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectations

Adjusted EBITDA for Q4 FY 2025 missed analyst estimates

Operating loss decreased 48.5% to $6.8 mln in Q4 FY 2025

Outlook

Company did not provide specific guidance for future periods

Result Drivers

DSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenue

RMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating income

LEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$138.1 mln
$135.61 mln (2 Analysts)
Q4 EPS
-$0.25
Q4 Net Income
-$8.60 mln
Q4 Adjusted EBITDA
Miss
$11.8 mln
$12.70 mln (2 Analysts)
Q4 Operating Income
-$6.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87

Press Release: ID:nGNX8SbVd1

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)